Helix BioPharma (TSE:HBP) Hits New 52-Week Low at $0.16

Helix BioPharma Corp. (TSE:HBPGet Rating)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as C$0.16 and last traded at C$0.17, with a volume of 22080 shares changing hands. The stock had previously closed at C$0.18.

Helix BioPharma Stock Up 5.9 %

The business’s 50 day moving average price is C$0.22 and its 200-day moving average price is C$0.22. The company has a debt-to-equity ratio of 2.60, a current ratio of 0.69 and a quick ratio of 0.67. The company has a market cap of C$31.38 million and a P/E ratio of -3.21.

Helix BioPharma (TSE:HBPGet Rating) last posted its earnings results on Tuesday, June 14th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. On average, analysts anticipate that Helix BioPharma Corp. will post -0.11 earnings per share for the current fiscal year.

Helix BioPharma Company Profile

(Get Rating)

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada.

Featured Stories

Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.